Market revenue in 2023 | USD 377.9 million |
Market revenue in 2030 | USD 672.8 million |
Growth rate | 8.6% (CAGR from 2023 to 2030) |
Largest segment | Coronary stents |
Fastest growing segment | Accessory Devices |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Intravascular Imaging Catheters and Pressure Guidewires, Coronary Stents, PTCA Balloon Catheters, Accessory Devices |
Key market players worldwide | Abbott Laboratories, Medtronic PLC, Boston Scientific Corp, Koninklijke Philips NV, Cardinal Health Inc, Terumo Corp, Teleflex Inc, B. Braun, Biosensors, BIOTRONIK, Asahi Intecc Co Ltd, Cook Medical, Merit Medical Systems Inc, Haemonetics Corp, Vascular Solutions, Zeon Corp, Alvimedica, Meril Life, Medinol |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to interventional cardiology devices market will help companies and investors design strategic landscapes.
Coronary stents was the largest segment with a revenue share of 50.33% in 2023. Horizon Databook has segmented the Italy interventional cardiology devices market based on intravascular imaging catheters and pressure guidewires, coronary stents, ptca balloon catheters, accessory devices covering the revenue growth of each sub-segment from 2018 to 2030.
Italy experienced a surge in deaths in 2020, with 100,000 more deaths compared to the average of the previous 5 years. The increase was most pronounced in individuals over 80 years of age, resulting in an excess of approximately 77,000 deaths in this age group. Italy joined the European Society of Cardiology Stent to ensure access to primary PCI for most ST-Segment–Elevation Myocardial Infarction (STEMI) cases.
Italy joined the European Society of Cardiology Stent to ensure access to primary PCI for most ST-Segment–Elevation Myocardial Infarction (STEMI) cases. In Italy, the Italian Medicines Agency (AIFA) evaluates the clinical & economic evidence for interventional cardiology devices and provides recommendations on their reimbursement.
The Italian National Health Service (Servizio Sanitario Nazionale) and regional health authorities determine the reimbursement rates for public healthcare providers based on these recommendations. Private insurance providers may have different reimbursement policies, which are determined independently.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy interventional cardiology devices market , including forecasts for subscribers. This country databook contains high-level insights into Italy interventional cardiology devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account